192 related articles for article (PubMed ID: 33382918)
1. A target-mediated drug disposition population pharmacokinetic model of GC1118, a novel anti-EGFR antibody, in patients with solid tumors.
Chung TK; Lee HA; Park SI; Oh DY; Lee KW; Kim JW; Kim JH; Woo A; Lee SJ; Bang YJ; Lee H
Clin Transl Sci; 2021 May; 14(3):990-1001. PubMed ID: 33382918
[TBL] [Abstract][Full Text] [Related]
2. Use of a Target-Mediated Drug Disposition Model to Predict the Human Pharmacokinetics and Target Occupancy of GC1118, an Anti-epidermal Growth Factor Receptor Antibody.
Park WS; Han S; Lee J; Hong T; Won J; Lim Y; Lee K; Byun HY; Yim DS
Basic Clin Pharmacol Toxicol; 2017 Mar; 120(3):243-249. PubMed ID: 27637171
[TBL] [Abstract][Full Text] [Related]
3. A First-in-Human Phase I Study of GC1118, a Novel Anti-Epidermal Growth Factor Receptor Antibody, in Patients with Advanced Solid Tumors.
Oh DY; Lee KW; Han SW; Kim JW; Shin JW; Jo SJ; Won J; Hahn S; Lee H; Kim WH; Bang YJ
Oncologist; 2019 Aug; 24(8):1037-e636. PubMed ID: 31164456
[TBL] [Abstract][Full Text] [Related]
4. Model Informed Dosing Regimen and Phase I Results of the Anti-PD-1 Antibody Budigalimab (ABBV-181).
Powderly J; Spira A; Kondo S; Doi T; Luke JJ; Rasco D; Gao B; Tanner M; Cassier PA; Gazzah A; Italiano A; Tosi D; Afar DE; Parikh A; Engelhardt B; Englert S; Lambert SL; Kasichayanula S; Mensing S; Menon R; Vosganian G; Tolcher A
Clin Transl Sci; 2021 Jan; 14(1):277-287. PubMed ID: 32770720
[TBL] [Abstract][Full Text] [Related]
5. A multicenter, phase II trial of GC1118, a novel anti-EGFR antibody, for recurrent glioblastoma patients with EGFR amplification.
Choi SW; Jung HA; Cho HJ; Kim TM; Park CK; Nam DH; Lee SH
Cancer Med; 2023 Aug; 12(15):15788-15796. PubMed ID: 37537946
[TBL] [Abstract][Full Text] [Related]
6. Quantitative modeling predicts competitive advantages of a next generation anti-NKG2A monoclonal antibody over monalizumab for the treatment of cancer.
Spinosa P; Musial-Siwek M; Presler M; Betts A; Rosentrater E; Villali J; Wille L; Zhao Y; McCaughtry T; Subramanian K; Liu H
CPT Pharmacometrics Syst Pharmacol; 2021 Mar; 10(3):220-229. PubMed ID: 33501768
[TBL] [Abstract][Full Text] [Related]
7. Population pharmacokinetics of the anti-PD-1 antibody camrelizumab in patients with multiple tumor types and model-informed dosing strategy.
Wang CY; Sheng CC; Ma GL; Xu D; Liu XQ; Wang YY; Zhang L; Cui CL; Xu BH; Song YQ; Zhu J; Jiao Z
Acta Pharmacol Sin; 2021 Aug; 42(8):1368-1375. PubMed ID: 33154554
[TBL] [Abstract][Full Text] [Related]
8. Population Pharmacokinetics of ABT-806, an Investigational Anti-Epidermal Growth Factor Receptor (EGFR) Monoclonal Antibody, in Advanced Solid Tumor Types Likely to Either Over-Express Wild-Type EGFR or Express Variant III Mutant EGFR.
Sharma S; Mittapalli RK; Holen KD; Xiong H
Clin Pharmacokinet; 2015 Oct; 54(10):1071-81. PubMed ID: 25761639
[TBL] [Abstract][Full Text] [Related]
9. Phase I first-in-human study of HLX07, a novel and improved recombinant anti-EGFR humanized monoclonal antibody, in patients with advanced solid cancers.
Hou MM; Ho CL; Lin HY; Zhu Y; Zhang X
Invest New Drugs; 2021 Oct; 39(5):1315-1323. PubMed ID: 33713216
[TBL] [Abstract][Full Text] [Related]
10. Efficacy and safety results of depatuxizumab mafodotin (ABT-414) in patients with advanced solid tumors likely to overexpress epidermal growth factor receptor.
Goss GD; Vokes EE; Gordon MS; Gandhi L; Papadopoulos KP; Rasco DW; Fischer JS; Chu KL; Ames WW; Mittapalli RK; Lee HJ; Zeng J; Roberts-Rapp LA; Loberg LI; Ansell PJ; Reilly EB; Ocampo CJ; Holen KD; Tolcher AW
Cancer; 2018 May; 124(10):2174-2183. PubMed ID: 29533458
[TBL] [Abstract][Full Text] [Related]
11. Alternative dosing regimens for atezolizumab: an example of model-informed drug development in the postmarketing setting.
Morrissey KM; Marchand M; Patel H; Zhang R; Wu B; Phyllis Chan H; Mecke A; Girish S; Jin JY; Winter HR; Bruno R
Cancer Chemother Pharmacol; 2019 Dec; 84(6):1257-1267. PubMed ID: 31542806
[TBL] [Abstract][Full Text] [Related]
12. Selection of dosing regimen with WST11 by Monte Carlo simulations, using PK data collected after single IV administration in healthy subjects and population PK modeling.
Fabre MA; Fuseau E; Ficheux H
J Pharm Sci; 2007 Dec; 96(12):3444-56. PubMed ID: 17854075
[TBL] [Abstract][Full Text] [Related]
13. Target-mediated drug disposition and prolonged liver accumulation of a novel humanized anti-CD81 monoclonal antibody in cynomolgus monkeys.
Vexler V; Yu L; Pamulapati C; Garrido R; Grimm HP; Sriraman P; Bohini S; Schraeml M; Singh U; Brandt M; Ries S; Ma H; Klumpp K; Ji C
MAbs; 2013; 5(5):776-86. PubMed ID: 23924796
[TBL] [Abstract][Full Text] [Related]
14. A phase I pharmacokinetic and pharmacodynamic study of dalotuzumab (MK-0646), an anti-insulin-like growth factor-1 receptor monoclonal antibody, in patients with advanced solid tumors.
Atzori F; Tabernero J; Cervantes A; Prudkin L; Andreu J; Rodríguez-Braun E; Domingo A; Guijarro J; Gamez C; Rodon J; Di Cosimo S; Brown H; Clark J; Hardwick JS; Beckman RA; Hanley WD; Hsu K; Calvo E; Roselló S; Langdon RB; Baselga J
Clin Cancer Res; 2011 Oct; 17(19):6304-12. PubMed ID: 21810918
[TBL] [Abstract][Full Text] [Related]
15. GC1118, an Anti-EGFR Antibody with a Distinct Binding Epitope and Superior Inhibitory Activity against High-Affinity EGFR Ligands.
Lim Y; Yoo J; Kim MS; Hur M; Lee EH; Hur HS; Lee JC; Lee SN; Park TW; Lee K; Chang KH; Kim K; Kang Y; Hong KW; Kim SH; Kim YG; Yoon Y; Nam DH; Yang H; Kim DG; Cho HS; Won J
Mol Cancer Ther; 2016 Feb; 15(2):251-63. PubMed ID: 26586721
[TBL] [Abstract][Full Text] [Related]
16. Promising Therapeutic Efficacy of GC1118, an Anti-EGFR Antibody, against KRAS Mutation-Driven Colorectal Cancer Patient-Derived Xenografts.
Lee HW; Son E; Lee K; Lee Y; Kim Y; Lee JC; Lim Y; Hur M; Kim D; Nam DH
Int J Mol Sci; 2019 Nov; 20(23):. PubMed ID: 31771279
[TBL] [Abstract][Full Text] [Related]
17. Population pharmacokinetic and covariate analysis of pertuzumab, a HER2-targeted monoclonal antibody, and evaluation of a fixed, non-weight-based dose in patients with a variety of solid tumors.
Garg A; Quartino A; Li J; Jin J; Wada DR; Li H; Cortés J; McNally V; Ross G; Visich J; Lum B
Cancer Chemother Pharmacol; 2014 Oct; 74(4):819-29. PubMed ID: 25119184
[TBL] [Abstract][Full Text] [Related]
18. Phase I pharmacokinetic and pharmacodynamic dose-escalation study of RG7160 (GA201), the first glycoengineered monoclonal antibody against the epidermal growth factor receptor, in patients with advanced solid tumors.
Paz-Ares LG; Gomez-Roca C; Delord JP; Cervantes A; Markman B; Corral J; Soria JC; Bergé Y; Roda D; Russell-Yarde F; Hollingsworth S; Baselga J; Umana P; Manenti L; Tabernero J
J Clin Oncol; 2011 Oct; 29(28):3783-90. PubMed ID: 21900113
[TBL] [Abstract][Full Text] [Related]
19. Population Target-Mediated Pharmacokinetic/Pharmacodynamic Modeling to Evaluate SPI-62 Exposure and Hepatic 11β-Hydroxysteroid Dehydrogenase Type 1 (HSD-1) Inhibition in Healthy Adults.
Wu N; Katz DA; An G
Clin Pharmacokinet; 2023 Sep; 62(9):1275-1288. PubMed ID: 37452998
[TBL] [Abstract][Full Text] [Related]
20. Population pharmacokinetic analysis of patritumab, a HER3 inhibitor, in subjects with advanced non-small cell lung cancer (NSCLC) or solid tumors.
Yoshiba S; Jansen M; Matsushima N; Chen S; Mendell J
Cancer Chemother Pharmacol; 2016 May; 77(5):987-96. PubMed ID: 27017616
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
